目的 探讨丹七软胶囊联合舒马普坦治疗偏头痛的临床疗效。方法 选取2017年1月-2019年4月于天津医科大学第二医院进行治疗的偏头痛患者126例，随机分为对照组和治疗组，每组各63例。对照组口服琥珀酸舒马普坦片，100 mg/次，1次/d。治疗组在对照组的基础上口服丹七软胶囊，5粒/次，3次/d，两组均连续治疗4周。观察两组的临床疗效，比较两组治疗前后头疼发作情况、血清基质金属蛋白酶-9（MMP-9）的变化情况。结果 治疗组治疗总有效率（95.24%）优于对照组（82.54%）（P<0.05）。治疗后两组患者头疼发作频次、发作程度评分均显著降低，头疼发作持续时间均显著缩短（P<0.05）；治疗后，治疗组头疼发作情况显著优于对照组（P<0.05）。治疗后，两组患者MMP-9均显著降低（P<0.05）；且治疗后治疗组MMP-9显著低于对照组（P<0.05）。结论 丹七软胶囊联合舒马普坦治疗偏头痛具有较好的临床疗效，能够有效改善患者血液流变学指标，减少头痛发作，具有一定的临床推广应用价值。

Objective To explore the effect of Danqi Soft Capsules combined with sumatriptan in treatment of migraine. Methods Patients (126 cases) with migraine who were treated in the Second Hospital of Tianjin Medical University from January 2017 to April 2019 were randomly divided into control group (63 cases) and treatment groups (63 cases). Patients in the control group were po administered with Sumatriptan Succinate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and changes of the headache onset and serum MMP-9 in two groups before and after treatment were compared. Results The total effective rate of the treatment group (95.24%) was better than that of the control group (82.54%) (P < 0.05). After treatment, the frequency and severity of headache attacks in both groups were significantly reduced, and the duration of headache attacks was significantly shortened (P < 0.05). After treatment, headache incidence in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, MMP-9 was significantly reduced in both groups (P < 0.05). After treatment, MMP-9 in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Danqi Soft Capsules combined with sumatriptan has good clinical efficacy in treatment of migraine, and can effectively improve hemorheology indicators of patients and reduce headache attacks, which has a certain clinical application value.

R971